In April 2024, that is last month, Suno India published the story featuring Iliyas Marandi, a 23-year-old tribal man who lost his eyesight after taking miltefosine drug for Post-Kala-azar Dermal Leishmaniasis, a skin manifestation of the deadly Kala-azar. This May, he underwent a corneal implant surgery at Indira Gandhi Institute of Medical Sciences. Suno India’s Menaka Rao spoke to Iliyas after the surgery, and his doctor, Dr Rakhi Kusumesh. This is Iliyas’s second corneal implant.

In 2022, the World Health Organization stated that 83 cases in India had possible links to miltefosine intake. While the government issued guidelines in 2022 to prevent people from losing vision after taking miltefosine, there are no plans yet for those who lost eyesight before 2022. Iliyas is one such person. He has so far mostly sought medical help with his own money, and resources. Except for some Ayushman Bharat scheme’s insurance money, Iliyas was on his own for this corneal implant too.

See sunoindia.in/privacy-policy for privacy information.

In this podcast episode, Suno India's Cofounder Rakesh speaks with Kaushik Shridhar, Founde & CEO, Orka Advisory and author of the book The Art of Winging It: What's the Worst That Could Happen?. He shares his journey from a professional tennis player to a career in sustainability. He discusses the inspiration behind his book and the lessons he has learned along the way. Kaushik emphasizes the importance of slowing down, appreciating life, and taking a positive approach to challenges. He also reflects on personal experiences, such as surviving a plane crash and overcoming bullying, and how they have shaped his perspective.

See sunoindia.in/privacy-policy for privacy information.

This is the last episode in the series on Kala Azar reported by Suno India’s Menaka Rao.

The Indian government has said that it has hit the elimination target for Kala-azar, a parasitic disease that is life-threatening. But miltefosine, the drug used to treat the skin manifestation of Kala-azar, called Post-Kala-azar Dermal Leishmaniasis (PKDL), is being linked to eye problems, including blindness.

The government has taken steps to try to reduce the side effects in 2021, but not much has been done for those who have lost their eyesight either in one eye or both, possibly as a result of miltefosine. The World Health Organization has found 83 cases of people in India who have suffered a problem in the eye after intake of miltefosine.

In this episode, Menaka spoke to Iliyas Marandi, one of the patients who lost his eyesight completely after taking miltefosine treatment. She also spoke to ophthalmologists Dr Rakhi Kushumesh and Dr Asim Sil who treated such patients, and helped develop the guidelines to prevent such ocular side effects.

References

https://www.indiaspend.com/health/how-a-drug-to-treat-dermal-kala-azar-is-affecting-patients-eyesight-901497

Keratitis occurring in patients treated with miltefosine for post-kala-azar dermal leishmaniasis | British Journal of Ophthalmology

https://ncvbdc.mohfw.gov.in/WriteReadData/l892s/PKDL-Guidelines-220512.pdf

Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme

Keratitis After Post-Kala-Azar Dermal Leishmaniasis

Corneal complications following Post Kala-azar Dermal Leishmaniasis treatment | PLOS Neglected Tropical Diseases

Adverse ocular events on miltefosine treatment for post-kala-azar dermal leishmaniasis in India - Suman Saurabh, Manish Mahabir, 2020

Advisory Committee on Safety of Medicinal Products (ACSoMP): Measures to minimize the risk of ocular adverse events with miltefosine

Statement on miltefosine - Potential ocular disorders in patients treated with miltefosine for post-kala-azar dermal leishmaniasis (PKDL).

See sunoindia.in/privacy-policy for privacy information.